207 studies found for:    Open Studies | "Triplets"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Triplets"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
3 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
4 Recruiting Cisplatin vs Paclitaxel for Triple Neg BRCA
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel;   Procedure: Pre- and Post-chemotherapy clinical diagnostic tissue
5 Recruiting Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Condition: Triple Negative Breast Cancer
Interventions: Procedure: Needle core biopsies;   Procedure: Needle core biopsies of metastatic lesion
6 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
7 Unknown  Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Paclitaxel plus carboplatin;   Drug: Paclitaxel and epirubicin
8 Unknown  Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
9 Recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
10 Unknown  Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
11 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
12 Not yet recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
13 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.
Interventions: Drug: CDX-011;   Drug: Capecitabine
14 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
15 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
16 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
17 Recruiting Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
18 Recruiting Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Intervention: Other: laboratory biomarker analysis
19 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
20 Recruiting A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: ENMD-2076

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years